Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects

BACKGROUND: PF-06650833 is a potent, selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). Two randomized, double-blind, sponsor-open phase 1 studies evaluated the safety, pharmacokinetics, and pharmacodynamics of single (SAD) and multiple ascending doses (MAD) of PF-06650833 im...

Descripción completa

Detalles Bibliográficos
Autores principales: Danto, Spencer I., Shojaee, Negin, Singh, Ravi Shankar P., Li, Cheryl, Gilbert, Steven A., Manukyan, Zorayr, Kilty, Iain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896740/
https://www.ncbi.nlm.nih.gov/pubmed/31805989
http://dx.doi.org/10.1186/s13075-019-2008-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896740/
https://www.ncbi.nlm.nih.gov/pubmed/31805989
http://dx.doi.org/10.1186/s13075-019-2008-6

Ejemplares similares